The Clinical Trials Transformation Initiative reflects on 10 years of working to improve the quality and efficiency of clinical trials. This article highlights many of the Clinical Trials Transformation Initiative's accomplishments and offers examples of the impact that the Clinical Trials Transformation Initiative has had on the clinical trials enterprise. After conducting more than 25 projects and issuing recommendations for specific strategies to improve the design and execution of clinical trials, some common themes and lessons learned have emerged. Lessons include the importance of engaging many stakeholders, advanced planning to address critical issues, discontinuation of non-value added practices, and new opportunities presented by technology. Through its work, the Clinical Trials Transformation Initiative has also derived some operational best practices for conducting collaborative, multi-stakeholder projects covering project selection, project team dynamics and execution, and multi-stakeholder meetings and team discussions. Through these initiatives, the Clinical Trials Transformation Initiative has helped move the needle toward needed change in the clinical trials enterprise that has directly impacted stakeholders and patients alike.
Background
The Clinical Trials Transformation Initiative (CTTI) was co-founded by the U.S. Food and Drug Administration and Duke University to improve efficiency and quality in clinical trials. CTTI now comprises a membership reflecting the diverse range of organizations involved in the design, conduct, and evaluation of clinical trials, as well as engages a vast array of stakeholders in its work. 1 Indeed, stakeholder engagement is much broader than membership, with individuals from more than 430 organizations having been involved in CTTI project teams or meetings. CTTI's mission is to develop and drive adoption of practices that will increase the quality and efficiency of clinical trials. Through a series of projects and collaborative efforts, CTTI offers solutions for significant improvements or advancements in clinical trials to stakeholders in the clinical trials enterprise (CTE) (Figure 1 ).
Pursuit of efficient and quality clinical trials
CTTI has conducted more than 25 projects within five strategic focus areas 2 and issued recommendations for specific actions and considerations to improve the design and execution of clinical trials, 3 with a goal of assuring meaningful, high-quality data and appropriate protection for participants ( Figure 2 ).
As described later in this article, our results and recommendations have been cited by government bodies and are being implemented by sponsors, academic organizations, patient advocacy groups, and others ( Figure 3 )-a testament to the importance of engaging people with diverse views through a process that results in evidence-based, consensus-driven, actionable recommendations to promote efficient, patient-centric clinical trials.
All CTTI recommendations and resources (tools, webinars, presentations, etc.) are freely available at www.ctti-clinicaltrials.org. Furthermore, all recommendations, and a description of many CTTI evidence gathering activities, are published elsewhere in peerreviewed journals, most of which are readily available through open-access. 4 Common themes identified in CTTI projects and recommendations CTTI projects span a wide array of topic areas, yet there are several themes that we have found to be important, regardless of topic.
Importance of engaging many stakeholders
First and foremost is engaging the right people. One of CTTI's core principles is to value the input and participation of all stakeholders, and we encourage others to do the same in nearly every set of project recommendations. Some recommendations also point to the importance of external input, as seen in the Recruitment Project recommendations, 5 which talk about the importance of seeking investigator/site and patient input regarding protocol feasibility. In addition, the quality by design (QbD) recommendations point to the value of bringing together multifunctional teams within organizations to develop quality protocols and appropriate risk mitigation plans. 6 Patients and caregivers offer unique perspectives about research, and CTTI recommends engaging these representatives throughout the clinical trial life cycle. 7 In viewing patients as partners throughout the design and conduct, trials become grounded in an operational framework that includes realistic inclusion/exclusion criteria, minimal burden, and endpoints that matter, while encouraging trust, accountability and transparent expectations between all stakeholders. Regulators are another stakeholder group that should be engaged when exploring innovative trial approaches, and early discussions can be particularly helpful.
Advanced planning to address critical issues CTTI defines clinical trial quality as the absence of errors that matter, that is, those errors that materially impact the rights and well-being of study participants or the reliability of the results. Many problems that may occur during a clinical trial can be prevented or mitigated through effective, proactive thought and planning. 8 Emerging from CTTI's work on clinical trial monitoring (typically a retrospective activity), the QbD project developed a new approach to build quality into the scientific and operational design of the clinical trial in a prospective and ongoing fashion. What worked for a previous trial on a similar medical product may not be the best approach for a new trial. Likewise, doing more of a given activity (e.g. collecting more data, and filling out more paperwork) may not improve and could even hurt the quality of a trial. The project recommendations, Critical to Quality Factors Principles Document, and QbD toolkit of resources help organizations that design, conduct, and sponsor clinical trials to develop a streamlined protocol and study design. This is accomplished by focusing on activities that are critical to ensure the credibility of study results and ensure the safety of trial participants, 9 engaging a broad range of stakeholders in trial planning, creating a culture that values critical thinking, and prospectively identifying and periodically checking critical to quality factors. 10 QbD has become a cornerstone of most CTTI project recommendations, promoting critical thinking upfront, encouraging appropriate training and oversight from relevant stakeholders, and promoting continued vigilance throughout the conduct of the clinical trial.
Discontinue non-value added practices
Recommendations from many projects suggest specific opportunities to focus on critical data and activities, with strategies to avoid activities that are not essential. As noted above, the QbD process asks us to consider whether non-essential activities may be eliminated from the study to simplify conduct, improve trial efficiency, and allocate resources to the most critical areas. In antibacterial drug development, where there is a huge public health need for new medical products, there is great interest in streamlining the development process. CTTI has collaborated with government and private stakeholders to identify strategies to streamline data collection and protocol elements for hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia (HABP/VABP) trials. 11 In another case, CTTI issued a series of recommendations to assist sponsors to comply with new regulations focusing on collection of the most important safety data. 12 There are also opportunities to reduce duplicative activities across clinical trials. CTTI conducted a project to address the Good Clinical Practices (GCP) training clinical research site staff received, which was often required by industry sponsors for each trial in which they participated, regardless of how many times they had previously received training. 13 We issued recommendations for a more efficient training process, and CTTI continues to evaluate whether training with or without complementary approaches is effective to ensure qualified investigators perform trials consistent with GCP. 14 
Technology presents new opportunities
Advances in novel technologies and increasing access to health data, such as electronic health records (EHRs), provide opportunities to increase the efficiency of many clinical trials and to improve the quality of the information that they provide. CTTI is working with many stakeholders to understand how we can take advantage of technology, while making sure that the results are reliable and participant protections remain robust.
Technology also offers the opportunity for people to more efficiently connect with one another. For example, social media presents an opportunity to reach out to a broader audience for recruitment purposes, and computers and smartphones can provide more direct interactions with trial participants, including providing new ways of obtaining informed consent. 15 However, it is important to evaluate the integration process when incorporating technology into clinical trials, so that the technology promotes increased efficiency and quality while omitting steps that do not add value.
Through streamlined data collection and the use of broader data sources, technology has promise for trial results that are more robust and the research itself more efficient. For example, mobile technologies (e.g. accelerometers and smartphones) allow capture of clinically relevant data related to physical function or patient symptoms that may be of relevance to particular conditions. Mobile technology offers the opportunity to capture real-world, real-time data more easily and may provide critical insights into disease areas not previously captured. CTTI's Mobile Clinical Trials program focuses on reducing barriers to the incorporation of mobile technology in Food and Drug Administration (FDA)-regulated clinical trials. 16 Likewise, the evolution of data sciences combined with technological advances presents opportunities. CTTI projects are exploring the application of existing data sources, such as the FDA Sentinel System, [17] [18] [19] registries and EHR systems for clinical trials. Linking randomized clinical trial data to routine healthcare records is promising, making efficient and unbiased assessment of the effects of a clinical intervention on a much broader range of clinical outcomes possible, once we overcome the practical challenges, such as the need for common terminology and standards for data exchange and integration.
While new technologies and integration of health data sources offer huge potential for better-quality clinical trials, capturing more (and more relevant) information on treatment effects more efficiently, they do not change the fundamental science of randomized trials (i.e. randomization, adherence to allocated therapy, completeness of follow-up, and intention-to-treat analyses remain critical). It is frequently CTTI's role to emphasize these points lest they be forgotten in all the excitement!
Lessons learned: successes and challenges
During these 10 years, we have learned some lessons about engaging a wide array of stakeholders across projects and focus areas. We continually strive to apply these lessons to ensure our projects make meaningful contributions to the ongoing efforts to improve clinical trial efficiency and quality.
Project selection
Targeting the collective needs and priorities of industry, academia, clinical trial sites, patients, and government bodies is fundamental to project success, and optimal adoption of the project recommendations occurs when the project results address the needs of relevant stakeholders. For example, regulators want evidence to help them develop new guidance documents, while sponsors want to know how to apply recommendations to their clinical trials and standard processes. In addition, project recommendations aligned with issues in the larger CTE can be built-up by other organizations, as was the case with TransCelerate Biopharma's risk-based monitoring work, which was complementary with CTTI's QbD recommendations, thus leading to greater adoption within the biopharmaceutical industry. 20 CTTI has fine-tuned its selection of projects to ensure key questions are considered upfront; examples include anticipated impact, criticality of issue, potential for transformation, regulatory needs, relationship to CTTI's current or past projects, and relationship to efforts of other organizations. While a formal selection process is important, there is also value in flexibility and responsiveness to important, emerging issues, which may have potential for meaningful impact but are not currently trending in the industry. For example, CTTI's project to facilitate a single institutional review board (IRB) of record for multi-center trials 21, 22 preceded the publication of the US Department of Health and Human Services (HHS) 2011 Advance Notice of Proposed Rulemaking (ANPRM) on human subjects protections. 23 
Project team dynamics and execution
At the organizational level, CTTI has also gained valuable experience regarding the importance of project team dynamics and execution. Enlisting knowledgeable, engaged, committed project leaders and team members representing diverse perspectives is crucial throughout the duration of the project. With a typical project spanning approximately 2 years, multi-stakeholder teams collaborate on all project activities, from gathering evidence related to the topic of interest, to formulating project recommendations and associated resources.
Passion in project team leaders and members is crucial because a passionate person is more likely to prioritize the project and work toward a meaningful solution. Passion also fuels the tireless advocate to ensure the necessary change occurs. However, sometimes the passion of one person may dominate the effort, overshadowing the diversity of stakeholders represented and creating barriers to reach a harmonious solution that takes all perspectives into account. Alternatively, team discussions may become unfocused at times, which can hamper project execution. We have learned that constantly monitoring team dynamics and progress allows us to intervene when needed to redirect discussions and support the team along the project plan trajectory.
Multi-stakeholder meetings, discussions, and project outputs CTTI strives to engage multi-stakeholder groups from project inception through project execution and beyond, as recommendations and tools are disseminated and adopted by those involved in clinical trials. CTTI has witnessed tremendous value in team discussions that lead to moments of common understanding between diverse stakeholders. These discussions are expanded during expert meetings designed to engage the wider trials community and allow issues to be explored further, solutions to be identified, and additional work can be determined. It is this culture of fostering collaborative discussions that allows the generation of innovative ideas and recommendations and that has allowed CTTI to move the needle toward a better clinical trial system. Understandably, not all project efforts are conducive to publishing a set of recommendations. In some cases, the evidence leads to publishing findings and sharing observations about the need for other courses of action, which inform the clinical trials community nonetheless. 24 A project scope may have been too broad or too narrow to meaningfully impact the greater clinical trials community. For example, CTTI's site metrics project 25 aimed to implement standardized measures of cycle times in study start-up (SSU) to understand what caused delays in SSU. We found, however, that the CTE is not collecting such standardized measures. Despite problems with collecting these cycle time measures, we found use of a central IRB was associated with shorter SSU. While no recommendations were created, the project team urged the CTE to 26 develop such measures. In other instances, the project recommendations may not be impactful in isolation, but the design and development of follow-on projects to explore solutions to complimentary challenges may create a synergistic effect in future use cases. Many factors contribute to a successful project, including clear direction by the project leadership, deep involvement of project members, strong project management, and identification of change agents within the community.
When a project struggled to make progress, or has not resulted in promoting meaningful change in the community, CTTI has found the root cause often points to the role of human factors. Keeping focus across a diverse group of stakeholders can be challenging. The very leaders and contributors identified as best-suited to tackle a particular project are often also those with the least amount of time to spare beyond their daily responsibilities. CTTI has found that engaging both leaders and junior associates, in addition to other creative approaches, have ensured our projects are supported by the best and brightest in the field, while simultaneously grooming future leaders.
In summary, CTTI has attempted to operationalize projects in areas of needed change, while considering broad and diverse engagement, and gathering evidence needed to inform those who regulate, sponsor, conduct, and participate in clinical trials. Fine-tuning our methods enables us to maximize project results and impact.
Impact to date and a look to the future While there is more work to be done to truly transform clinical trials, much has been accomplished in the past 10 years, and CTTI has made a difference (Figure 4 ). How do we know? The evidence we have generated and the recommendations we have issued have been considered by the FDA, the European Medicines Agency (EMA), the National Institutes of Health (NIH), and other policymaking organizations. 27 CTTI's Safety Reporting project 28 has been cited in FDA's draft guidance on safety assessment, 29 CTTI's Monitoring and Quality by Design project 30 was referenced in regulatory guidance documents by both the FDA 31 and the EMA, 32 and CTTI's Central IRB project 33, 34 was cited in the Request for Comments on the Draft Policy by the National Institutes of Health on the Use of a Single Institutional Review Board for Multi-Site Research. 35 A regulatory policy change can be an important driver to a larger cultural shift in the way trials are conducted. For example, when new guidance, regulations, or policies encourage or require the use of a central IRB, quality risk management approaches, streamlined safety reporting, or the use of technology and evidence generation using real-world data, community stakeholders respond to implement the necessary changes. CTTI is among the initiatives that have provided recommendations and resources to support the clinical trials community in making these changes.
Furthermore, we have examples of academic centers, industry, professional societies, and trade and patient organizations who have used CTTI recommendations to improve their processes for these and other aspects of the design and conduct of clinical trials.
For example, the Duke Clinical Research Institute recently appointed a new Director of Quality by Design and is working to implement CTTI's recommended QbD approach both in its organizational culture and in its approach to protocol design and operation (personal communication, Maureen Cunningham, 17 July 2017).
Research sponsor Genentech is streamlining their informed consent document using CTTI's informed consent recommendations for a ''tiered approach'' to consent forms 15, 36 (personal communications, Virginia Nido, 11 July 2017). In addition, Eli Lilly successfully piloted the ''tiered approach'' to consent forms and is implementing e-consent in accordance with CTTI rec- July 2017), which has utilized tools to require the use of, serve as, or cede review to a single IRB of record. 33 We are developing formal case studies of each of these examples and others, so organizations can learn from one another's successes.
Change can be more easily achieved when all stakeholders are involved. We have shown that not all change needs to be transformative; in fact, incremental improvements to routine processes, such as informed consent, can lead to better-quality trials over time. CTTI's vision is a high-quality clinical trial system that is patient-centered and efficient, enabling reliable and timely access to evidence-based therapeutic prevention and treatment options-ultimately improving public health.
No effort is without its challenges, but as CTTI celebrates 10 years of successfully driving change in the CTE, we are committed to efforts that question the status quo and work with all stakeholders to make clinical trials more efficient, quality-driven, and patient-focused.
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